Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on January 2, 2025 (the “Grant Date”), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback